[go: up one dir, main page]

WO2003104392A3 - IMPROVED REAGENTS AND METHODS FOR PRODUCING PARVOVIRUSES - Google Patents

IMPROVED REAGENTS AND METHODS FOR PRODUCING PARVOVIRUSES Download PDF

Info

Publication number
WO2003104392A3
WO2003104392A3 PCT/US2002/038423 US0238423W WO03104392A3 WO 2003104392 A3 WO2003104392 A3 WO 2003104392A3 US 0238423 W US0238423 W US 0238423W WO 03104392 A3 WO03104392 A3 WO 03104392A3
Authority
WO
WIPO (PCT)
Prior art keywords
parvoviruses
producing
methods
improved reagents
coding sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/038423
Other languages
French (fr)
Other versions
WO2003104392A9 (en
WO2003104392A2 (en
Inventor
Richard Jude Samulski
Joseph E Rabinowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Priority to AU2002367943A priority Critical patent/AU2002367943A1/en
Publication of WO2003104392A2 publication Critical patent/WO2003104392A2/en
Publication of WO2003104392A9 publication Critical patent/WO2003104392A9/en
Anticipated expiration legal-status Critical
Publication of WO2003104392A3 publication Critical patent/WO2003104392A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur des polynucléotides comprenant les séquences de codage rep de parvovirus chimères (par exemple AAV). Lesdits polynucléotides codent facultativement pour les séquences de codage cap de parvovirus L'invention porte également sur des vecteurs et cellules comprenant les polynucléotides de l'invention, et sur des procédés améliorés de constitution de stocks de parvovirus hybrides utilisant les séquences de codage rep de parvovirus chimères de l'invention.Polynucleotides comprising the rep coding sequences of chimeric parvoviruses (eg AAV) are provided. Said polynucleotides optionally code for the parvovirus cap coding sequences chimeras of the invention.

PCT/US2002/038423 2001-12-18 2002-12-02 Improved reagents and methods for producing parvoviruses Ceased WO2003104392A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002367943A AU2002367943A1 (en) 2001-12-18 2002-12-02 Improved reagents and methods for producing parvoviruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34191901P 2001-12-18 2001-12-18
US60/341,919 2001-12-18

Publications (3)

Publication Number Publication Date
WO2003104392A2 WO2003104392A2 (en) 2003-12-18
WO2003104392A9 WO2003104392A9 (en) 2004-04-29
WO2003104392A3 true WO2003104392A3 (en) 2004-08-05

Family

ID=29735975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038423 Ceased WO2003104392A2 (en) 2001-12-18 2002-12-02 Improved reagents and methods for producing parvoviruses

Country Status (2)

Country Link
AU (1) AU2002367943A1 (en)
WO (1) WO2003104392A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2772989C2 (en) * 2017-09-19 2022-05-30 Сивек Фармасьютикалз Гмбх INDUCIBLE Rep AAV GENES

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
NZ618298A (en) 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
JP4810062B2 (en) 2001-12-17 2011-11-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Sequence of adeno-associated virus (AAV) serotype 8
MX377804B (en) 2014-03-09 2025-03-11 Univ Pennsylvania COMPOSITIONS USEFUL IN THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY.
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017155973A1 (en) 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
EP3456822A1 (en) * 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
JP2021514659A (en) 2018-03-06 2021-06-17 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド AAV chimera
CN108465107B (en) * 2018-06-05 2020-02-21 山东信得科技股份有限公司 Duck type 2 adenovirus and Muscovy duck parvovirus disease combined inactivated vaccine
EP3891290A4 (en) * 2018-12-21 2022-11-02 Lonza Walkersville, Inc. ADENO-ASSOCIATED VIRUS (AAV) PRODUCER CELL LINE AND RELATED METHODS
US10557149B1 (en) * 2019-07-15 2020-02-11 Vigene Biosciences, Inc. Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
US20250320521A1 (en) * 2022-05-09 2025-10-16 Synteny Therapeutics, Inc. Erythroparvovirus compositions and methods for gene therapy
EP4522210A1 (en) * 2022-05-09 2025-03-19 Synteny Therapeutics, Inc. Erythroparvovirus with a modified genome for gene therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CATHOMEN ET AL: "A chimeric protein containing the N-terminus of the adeno-associated virus rep protein recognizes its target site in an in vivo assay", J. OF VIROLOGY, vol. 74, no. 5, March 2000 (2000-03-01), pages 2372 - 2382, XP002978182 *
YOON ET AL: "Amino-terminal domain exchange redirects origin-specific interactions of adeno-associated virus rep78 in vitro", J. OF VIROLOGY, vol. 75, no. 7, April 2001 (2001-04-01), pages 3230 - 3239, XP002978181 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2772989C2 (en) * 2017-09-19 2022-05-30 Сивек Фармасьютикалз Гмбх INDUCIBLE Rep AAV GENES

Also Published As

Publication number Publication date
WO2003104392A9 (en) 2004-04-29
AU2002367943A8 (en) 2003-12-22
AU2002367943A1 (en) 2003-12-22
WO2003104392A2 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
WO2003104392A3 (en) IMPROVED REAGENTS AND METHODS FOR PRODUCING PARVOVIRUSES
PT698105E (en) NUCLEOTIDED SEQUENCES FOR CONTROL OF EXPRESSION OF DNA SEQUENCES IN A CELLULAR HOST
CY1111126T1 (en) KETOTIFAINE CONTAINING OPTIMAL DROPS
AU7494701A (en) Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
ATE437184T1 (en) VARIANTS OF THE FC REGION
DE69709561D1 (en) Estrogen receptor
NO962188D0 (en) Novel apoptosis modulating proteins, DNA encoding the proteins and methods for their use
DE60232909D1 (en) GLOSS POLISHING OF DIAMONDIC CARBON FOR IMPROVED WEAR RESISTANCE
ATE425180T1 (en) A CHIMERIC PROTEIN CONTAINING NON-TOXIC PSEUDOMONAS EXOTOXIN A AND TYPE IV PILIN SEQUENCES
DE602004023757D1 (en) METHOD FOR CLEANING FSH
WO2003004681A3 (en) Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
ATE394509T1 (en) OLIGONUCLEOTIDES CONTAINING MOLECULAR RODS
ATE169343T1 (en) COMMONLY USED GENETIC MARKERS FOR DIAGNOSTIC ALZHEIMER'S DISEASE, METHOD AND DIAGNOSTIC REAGENT SET
AU9408801A (en) Schizophrenia related gene and protein
EP0948512A4 (en) METHOD FOR SYNTHESIZING OLIGONUCLEOTIDES PHOSPHOROTHIOATES
BR9908872A (en) Water purification method
ATE370250T1 (en) DETECTION OF PATHOGENIC BACTERIA
DE69942200D1 (en) Parvovirus NS1 variants
ATE303442T1 (en) COMPOUNDS FROM MORAXELLA CATARRHALIS
DE60040668D1 (en) ANTIBACTERIAL PROTEIN CHLAMINEIN-B, GENE FOR THE CODING GENE AND AN EXPRESSION SYSTEM THEREFOR
NO20011961D0 (en) The PRV-1 gene and its use
ATE397666T1 (en) NEW COMPOUNDS FROM MORAXELLA CATARRHALIS
ATE319826T1 (en) MINIMUM PROMOTORS AND THEIR USE
ATE372788T1 (en) CONTRAST AGENTS CONSISTING OF GEOMETRICALLY HIGHLY ORDERED PROTEINS FOR MEDICAL DIAGNOSTICS
WO2003011906A3 (en) Use of peptide fragments of the calcium channel α-1 subunit, optionally comprising mutations, for screening molecules of therapeutic interest

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/36-36/36, DRAWINGS, REPLACED BY NEW PAGES 1/60-60/60; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP